Accelerating Cancer Immunotherapy Research

What Accelerating Cancer Immunotherapy Research does

Accelerating Cancer Immunotherapy Research (ACIR) is a U.S.-based nonprofit knowledge platform, operating under The Fritsch Foundation, that aggregates and disseminates cancer immunotherapy research literature to the global research community. Founded circa 2015 and headquartered in Concord, Massachusetts (with Cambridge-area connections evidenced by its 2019 Chamber of Commerce recognition), ACIR runs a small volunteer-led team of 1-10 contributors that produces five integrated content products: Weekly Digests (curated literature summaries delivered via email newsletter), a searchable Literature Database of peer-reviewed publications, a Knowledge Base of educational resources, the ACIR Podcast, and Events coverage of major cancer immunotherapy conferences. Content distribution leverages Mailchimp for email delivery and organic social channels including LinkedIn, Facebook, X, and Bluesky, with all material provided free of charge to end users.

The organization's revenue model is donation- and sponsorship-based rather than transactional, reflecting its nonprofit status. ACIR reports Genentech as a named current sponsor, alongside an anonymous donor-advised fund, individual reader donations, and a RoundUp App micro-donation partnership processed via Stripe and Raisely. Operational and infrastructure support is provided by its parent, The Fritsch Foundation. ACIR holds a GuideStar Transparency Seal and operates GDPR-compliant marketing permissions, with notable third-party validation including the Cambridge Chamber of Commerce Visionary Award (November 2019) and a Bloomberg TV feature in The American Dream (September 2020). The organization celebrated its 10th anniversary with a leadership transition in 2025, and public testimonials from leading researchers such as Carl H. June, MD of the University of Pennsylvania underline its standing within the cancer immunotherapy academic community.

From a go-to-market perspective, ACIR pursues a community-led motion with no traditional sales force: content marketing (the digests themselves), researcher testimonials, podcast interviews, and conference coverage function as both product and acquisition channels. The primary customer segment is academic and industry cancer immunotherapy researchers at universities, research institutes, pharmaceutical companies, and hospitals involved in immunotherapy development and clinical trials. Geographic reach is global via web and email, with no stated market restrictions.

Name

Accelerating Cancer Immunotherapy Research

Legal name

Accelerating Cancer Immunotherapy Research

Website

https://acir.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

ACIR is a U.S. nonprofit knowledge platform under The Fritsch Foundation that curates cancer immunotherapy research literature into weekly email digests, a searchable database, a podcast, and conference coverage for academic and industry researchers globally.

Ownership category

akta.pro rank

Product category

Cancer Research Content Curation

NAICS

Web Search Portals, Libraries, Archives, and Other Information Services (5192)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Cancer immunotherapy research
• Research literature summaries
• Scientific literature curation
• Medical research digests
• Immunotherapy research news

Headquarters

HQ city

Concord

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Donations and Charitable Contributions: ACIR operates as a non-profit supported by donations from individuals, readers, and sponsors. Current sponsors include Genentech and anonymous donors. The organization accepts donations through its Raisely fundraising platform and RoundUp App for micro-donations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ACIR is a nonprofit knowledge platform that aggregates, summarizes, and disseminates peer-reviewed cancer immunotherapy research literature. It provides weekly curated digests with illustrations, a searchable literature database, a knowledge base of educational resources, a podcast featuring researcher interviews, and coverage of relevant conferences and meetings. Content is provided free to the research community and supported by donations and sponsorships.

Product overview

ACIR is a nonprofit knowledge platform that aggregates and summarizes cancer immunotherapy research literature. The organization operates as a unified content platform offering five integrated services: Weekly Digests (expert-curated literature summaries delivered via newsletter), a searchable Literature Database, a Knowledge Base repository, an ACIR Podcast for audio content, and Events coverage. Together, these offerings help cancer immunotherapy researchers stay current with the rapidly evolving literature in this multifaceted field.

Differentiator

Problem solved

Functional benefit

Products and services

• Weekly Digests Weekly newsletter providing clear, concise, and insightful summaries of new cancer immunotherapy literature, complemented by expert-curated images and analysis. Distributed free to subscribers via email. Targeted at cancer immunotherapy researchers in academia and industry.
• Knowledge Base A comprehensive repository of educational and informational resources covering various aspects of cancer immunotherapy research. Free access via the ACIR website. Targeted at cancer immunotherapy researchers and students.
• Literature Database A searchable database of peer-reviewed journal articles and scientific publications related to cancer immunotherapy, allowing researchers to search and filter by tags and topics. Free access via the ACIR website. Targeted at cancer immunotherapy researchers.
• ACIR Podcast An audio program featuring discussions, interviews, and educational content about the latest developments in cancer immunotherapy research. Free access via podcast platforms. Targeted at cancer immunotherapy researchers and broader interested audience.
• Events Coverage Coverage and information about conferences and meetings relevant to the cancer immunotherapy research community. Free access via the ACIR website. Targeted at cancer immunotherapy researchers, clinicians, and industry professionals.

Quantifiable outcome

• Weekly newsletter service supporting researchers in staying current with rapidly evolving cancer immunotherapy literature

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• GuidestarminorOthersACIR holds Guidestar's Transparency Seal, demonstrating commitment to organizational transparency as a non-profit.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Science Daily: Science Daily aggregates and summarizes peer-reviewed scientific publications across disciplines with plain-language write-ups. It shares ACIR's model of distilling primary research into accessible summaries for a research-adjacent audience, and operates at much larger scale across all of science.
• The Scientist: The Scientist is a magazine and digital publication covering life science research with curated news, expert commentary, and educational content. Like ACIR, it provides value through editorial synthesis of complex biomedical research for working scientists, though across all of life science rather than one therapeutic area.
• Faculty Opinions (formerly F1000): Faculty Opinions curates and peer-reviews biomedical literature with expert commentary, closely mirroring ACIR's model of expert-vetted research summaries. Both serve researchers who need synthesized insights from the primary literature, though Faculty Opinions operates across all of biomedicine rather than restricting to cancer immunotherapy.
• STAT News: STAT News produces deep coverage of the biopharma, biotech, and health research industries, including analysis of clinical trial results and scientific breakthroughs. Like ACIR, it helps its audience interpret new research, though STAT focuses on the business and policy lens across all of health rather than deep scientific curation in one niche.

Others

• BioRender: BioRender is a scientific illustration and figure-creation platform used by life science researchers, including for the kind of figures ACIR incorporates into its digests. It is an enabling tool for the research communication workflow rather than a direct content competitor, though its users overlap substantially with ACIR's audience.
• ResearchGate: ResearchGate is a professional network for scientists and researchers that surfaces publications, Q&A, and discussion. It serves the same cancer immunotherapy research community ACIR targets but focuses on researcher-to-researcher discovery rather than top-down expert curation.

Broad incumbents

• Frontiers: Frontiers is a major open-access scientific publisher operating journals across biomedicine including oncology and immunology. While primarily a publisher rather than curator, Frontiers hosts and surfaces the same underlying cancer immunotherapy research that ACIR summarizes, and competes for the attention of the same research audience.
• Nature Briefing: Nature Briefing is a daily/weekly email digest from the Nature publishing group that summarizes key new scientific papers and research news. It is directly comparable to ACIR's weekly digests in format and function, but is delivered by a large incumbent publisher and covers all of science.

Emerging players

• Abridged: Abridged provides concise, curated summaries of new scientific papers for researchers who want to keep up with the literature. It is a direct functional analog to ACIR's weekly digests, though it operates as a startup-style platform across all of science rather than a focused non-profit in one therapeutic area.
• BenchSci: BenchSci is an AI-powered biomedical research platform that helps scientists find relevant reagents, antibodies, and published evidence. It intersects with ACIR's audience (biomedical researchers) and increasingly overlaps in AI-driven literature summarization, though BenchSci's commercial SaaS model and reagent focus differ from ACIR's free curation model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ACIR_org
• Facebookfacebook.com/ACIRorg
• LinkedInlinkedin.com/company/acir

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelerating Cancer Immunotherapy Research